Targeting the toll of drug abuse: The translational potential of toll-like receptor 4

CNS and Neurological Disorders - Drug Targets

Volumn 14, Issue 6, 2015, Pages 692-698

  Bachtell, Ryan ^a   Hutchinson, Mark R ^b   Wang, Xiaohui ^a   Rice, Kenner C ^c   Maier, Steven F ^a   Watkins, Linda R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

(+) naloxone; (+) naltrexone; Alcohol; Cocaine; Drug reinforcement; Drug reward; Morphine; Opioid; Psychostimulants; Reinstatement

Indexed keywords

4 AMINOBUTYRIC ACID; ALCOHOL; AMPA RECEPTOR; BIOLOGICAL FACTOR; CD11B ANTIGEN; COCAINE; DOPAMINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; METHAMPHETAMINE; MYELOID DIFFERENTIATION FACTOR 2; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NALOXONE; NALTREXONE; NITRIC OXIDE; OPIATE; PROTEIN MD 2; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; XENOBIOTIC AGENT; NARCOTIC ANTAGONIST;

ARTICLE; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL (TOPIC); DRUG ABUSE; DRUG BINDING SITE; DRUG SELF ADMINISTRATION; GLIA CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; INTRACELLULAR SIGNALING; MICROGLIA; MOLECULAR DOCKING; MOLECULAR RECOGNITION; NONHUMAN; NUCLEUS ACCUMBENS SHELL; WITHDRAWAL SYNDROME; ANIMAL; DRUG EFFECTS; GLIA; METABOLISM; NERVE CELL; PATHOLOGY; PHYSIOLOGY; REWARD; SUBSTANCE-RELATED DISORDERS;

ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; NALTREXONE; NARCOTIC ANTAGONISTS; NEUROGLIA; NEURONS; REWARD; SUBSTANCE-RELATED DISORDERS; TOLL-LIKE RECEPTOR 4; XENOBIOTICS;

EID: 84933071385     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527314666150529132503     Document Type: Article

References (71)

1. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009; 458: 1191-5.
2. Hutchinson MR, Watkins LR. Why is neuroimmunopharmacology crucial for the future of addiction research? Neuropharmacology 2014; 76 Pt B: 218-27.
3. Grace PM, Hutchinson MR, Maier SF, Watkins LR. Pathological pain and the neuroimmune interface. Nat Rev Immunol 2014; 14: 217-31.
4. Mayer DJ, Mao J, Holt J, Price DD. Cellular mechanisms of neuropathic pain, morphine tolerance, and their interactions. Proc Natl Acad Sci USA 1999; 96: 7731-6.
5. Song P, Zhao ZQ. The involvement of glial cells in the development of morphine tolerance. Neurosci Res 2001; 39: 281-6.
6. Fairbanks CA, Wilcox GL. Spinal plasticity of acute opioid tolerance. J Biomed Sci 2000; 7: 200-12.
7. Hutchinson MR, Shavit Y, Grace PM, Rice KC, Maier SF, Watkins LR. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev 2011; 63: 772-810.
8. Watkins LR, Hutchinson MR, Ledeboer A, Wieseler-Frank J, Milligan ED, Maier SF. Norman Cousins Lecture. Glia as the "bad guys": implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun 2007; 21: 131-46.
9. Beitner-Johnson D, Guitart X, Nestler EJ. Glial fibrillary acidic protein and the mesolimbic dopamine system: regulation by chronic morphine and Lewis-Fischer strain differences in the rat ventral tegmental area. J Neurochem 1993; 61: 1766-73.
10. Hutchinson MR, Zhang Y, Shridhar M, et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 2010; 24: 83-95.
11. Hutchinson MR, Lewis SS, Coats BD, et al. Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience 2010; 167: 880-93.
12. Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci 2008; 28: 20-9.
13. Wang X, Loram LC, Ramos K, et al. Morphine activates neuroinflammation in a manner parallel to endotoxin. Proc Natl Acad Sci USA 2012; 109: 6325-30.
14. Northcutt A, Hutchinson M, Wang X, et al. DAT isn't all that: cocaine reward and reinforcement requires Toll Like Receptor 4 signaling. Mol Psychiatry 2014; Epub ahead of print.
15. Blanco AM, Valles SL, Pascual M, Guerri C. Involvement of TLR4/type I IL-1 receptor signaling in the induction of inflammatory mediators and cell death induced by ethanol in cultured astrocytes. J Immunol 2005; 175: 6893-9.
16. Nicotra L, Loram LC, Watkins LR, Hutchinson MR. Toll-like receptors in chronic pain. Exp Neurol 2012; 234: 316-29.
17. Meng J, Gong M, Bjorkbacka H, Golenbock DT. Genome-wide expression profiling and mutagenesis studies reveal that lipopolysaccharide responsiveness appears to be absolutely dependent on TLR4 and MD-2 expression and is dependent upon intermolecular ionic interactions. J Immunol 2011; 187: 3683-93.
18. Traber DL, Thomson PD, Blalock JE, et al. Action of an opiate receptor blocker on ovine cardiopulmonary responses to endotoxin. Am J Physiol 1983; 245: H189-93.
19. Sziebert L, Thomson PD, Jinkins J, et al. Effect of naloxone treatment on the cardiopulmonary response to endotoxin in sheep. Adv Shock Res 1983; 10: 121-8.
20. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 1998; 95: 588-93.
21. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282: 2085-8.
22. Bajo M, Madamba SG, Roberto M, et al. Innate immune factors modulate ethanol interaction with GABAergic transmission in mouse central amygdala. Brain Behav Immun 2014; 40: 191-202.
23. Ahmadi A, Sayyah M, Khoshkholgh-Sima B, et al. Intrahippocampal injection of lipopolysaccharide inhibits kindled seizures and retards kindling rate in adult rats. Exp Brain Res 2013; 226: 107-20.
24. Sayyah M, Javad-Pour M, Ghazi-Khansari M. The bacterial endotoxin lipopolysaccharide enhances seizure susceptibility in mice: involvement of proinflammatory factors: nitric oxide and prostaglandins. Neuroscience 2003; 122: 1073-80.
25. Xu YF, Fu LL, Jiang CH, Qin YW, Ni YQ, Fan JW. Naloxone inhibition of lipopolysaccharide-induced activation of retinal microglia is partly mediated via the p38 mitogen activated protein kinase signalling pathway. J Int Med Res 2012; 40: 1438-48.
26. Jiang X, Ni Y, Liu T, Zhang M, Ren H, Xu G. Inhibition of LPSinduced retinal microglia activation by naloxone does not prevent photoreceptor death. Inflammation 2013; 36: 42-52.
27. Block L, Forshammar J, Westerlund A, et al. Naloxone in ultralow concentration restores endomorphin-1-evoked Ca(2)(+) signaling in lipopolysaccharide pretreated astrocytes. Neuroscience 2012; 205: 1-9.
28. Wang TY, Su NY, Shih PC, Tsai PS, Huang CJ. Anti-inflammation effects of naloxone involve phosphoinositide 3-kinase delta and gamma. J Surg Res 2014; 192(2): 599-606.
29. Wang Q, Zhou H, Gao H, et al. Naloxone inhibits immune cell function by suppressing superoxide production through a direct interaction with gp91phox subunit of NADPH oxidase. J Neuroinflammation 2012; 9: 32.
30. Liu SL, Li YH, Shi GY, et al. A novel inhibitory effect of naloxone on macrophage activation and atherosclerosis formation in mice. J Am Coll Cardiol 2006; 48: 1871-9.
31. Shen D, Cao X, Zhao L, Tuo J, Wong WT, Chan CC. Naloxone ameliorates retinal lesions in Ccl2/Cx3cr1 double-deficient mice via modulation of microglia. Invest Ophthalmol Vis Sci 2011; 52: 2897-904.
32. Zhang P, Lokuta KM, Turner DE, Liu B. Synergistic dopaminergic neurotoxicity of manganese and lipopolysaccharide: differential involvement of microglia and astroglia. J Neurochem 2010; 112: 434-43.
33. Liu B, Jiang JW, Wilson BC, et al. Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J Pharmacol Exp Ther 2000; 295: 125-32.
34. Liu B, Du L, Kong LY, et al. Reduction by naloxone of lipopolysaccharide-induced neurotoxicity in mouse cortical neuronglia co-cultures. Neuroscience 2000; 97: 749-56.
35. Wang CC, Cheng PY, Peng YJ, Wu ES, Wei HP, Yen MH. Naltrexone protects against lipopolysaccharide/D-galactosamineinduced hepatitis in mice. J Pharmacol Sci 2008; 108: 239-47.
36. Lin SL, Lee YM, Chang HY, Cheng YW, Yen MH. Effects of naltrexone on lipopolysaccharide-induced sepsis in rats. J Biomed Sci 2005; 12: 431-40.
37. Greeneltch KM, Haudenschild CC, Keegan AD, Shi Y. The opioid antagonist naltrexone blocks acute endotoxic shock by inhibiting tumor necrosis factor-alpha production. Brain Behav Immun 2004; 18: 476-84.
38. Xiao E, Xia-Zhang L, Ferin M. Inhibitory effects of endotoxin on LH secretion in the ovariectomized monkey are prevented by naloxone but not by an interleukin-1 receptor antagonist. Neuroimmunomodulation 2000; 7: 6-15.
39. Romanovsky AA, Shido O, Ungar AL, Blatteis CM. Peripheral naloxone attenuates lipopolysaccharide fever in guinea pigs by an action outside the blood-brain barrier. Am J Physiol 1994; 266: R1824-31.
40. Hutchinson MR, Ramos KM, Loram LC, et al. Evidence for a role of heat shock protein-90 in toll like receptor 4 mediated pain enhancement in rats. Neuroscience 2009; 164: 1821-32.
41. Wu HE, Sun HS, Cheng CW, Terashvili M, Tseng LF. dextro-Naloxone or levo-naloxone reverses the attenuation of morphine antinociception induced by lipopolysaccharide in the mouse spinal cord via a non-opioid mechanism. Eur J Neurosci 2006; 24: 2575-80.
42. Johnston IN, Westbrook RF. Inhibition of morphine analgesia by LPS: role of opioid and NMDA receptors and spinal glia. Behav Brain Res 2005; 156: 75-83.
43. Liu B, Du L, Hong JS. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J Pharmacol Exp Ther 2000; 293: 607-17.
44. Lewis SS, Loram LC, Hutchinson MR, et al. (+)-naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats. J Pain 2012; 13: 498-506.
45. Hutchinson MR, Northcutt AL, Hiranita T, et al. Opioid activation of toll-like receptor 4 contributes to drug reinforcement. J Neurosci 2012; 32: 11187-200.
46. Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology 2010; 35: 217-38.
47. Thomas MJ, Kalivas PW, Shaham Y. Neuroplasticity in the mesolimbic dopamine system and cocaine addiction. Br J Pharmacol 2008; 154: 327-42.
48. Crews F, Nixon K, Kim D, et al. BHT blocks NF-kappaB activation and ethanol-induced brain damage. Alcohol Clin Exp Res 2006; 30: 1938-49.
49. Zou J, Crews F. Induction of innate immune gene expression cascades in brain slice cultures by ethanol: key role of NF-kappaB and proinflammatory cytokines. Alcohol Clin Exp Res 2010; 34: 777-89.
50. Alfonso-Loeches S, Pascual-Lucas M, Blanco AM, Sanchez-Vera I, Guerri C. Pivotal role of TLR4 receptors in alcohol-induced neuroinflammation and brain damage. J Neurosci 2010; 30: 8285-95.
51. Bell RL, Lopez MF, Cui C, et al. Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence. Addict Biol 2013; 20(1): 38-42.
52. Li XC, Karadsheh MS, Jenkins PM, Stitzel JA. Genetic correlation between the free-choice oral consumption of nicotine and alcohol in C57BL/6JxC3H/HeJ F2 intercross mice. Behav Brain Res 2005; 157: 79-90.
53. Wu Y, Lousberg EL, Moldenhauer LM, et al. Inhibiting the TLR4-MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol-induced sedation and motor impairment in mice. Br J Pharmacol 2012; 165: 1319-29.
54. Yang H, Hreggvidsdottir HS, Palmblad K, et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010; 107: 11942-7.
55. Jacobsen JH, Watkins LR, Hutchinson MR. Discovery of a Novel Site of Opioid Action at the Innate Immune Pattern-Recognition Receptor TLR4 and its Role in Addiction. Int Rev Neurobiol 2014; 118: 129-63.
56. Narita M, Miyatake M, Narita M, et al. Direct evidence of astrocytic modulation in the development of rewarding effects induced by drugs of abuse. Neuropsychopharmacology 2006; 31: 2476-88.
57. Shen H, Hu X, Szymusiak M, Wang ZJ, Liu Y. Orally administered nanocurcumin to attenuate morphine tolerance: comparison between negatively charged PLGA and partially and fully PEGylated nanoparticles. Mol Pharm 2013; 10: 4546-51.
58. Hutchinson MR, Lewis SS, Coats BD, et al. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast). Brain Behav Immun 2009; 23: 240-50.
59. Theberge FR, Li X, Kambhampati S, et al. Effect of chronic delivery of the Toll-like receptor 4 antagonist (+)-naltrexone on incubation of heroin craving. Biol Psychiatry 2013; 73: 729-37.
60. Schwacha MG. Opiates and the development of post-injury complications: a review. Int J Clin Exp Med 2008; 1: 42-9.
61. Wang J, Barke RA, Ma J, Charboneau R, Roy S. Opiate abuse, innate immunity, and bacterial infectious diseases. Arch Immunol Ther Exp 2008; 56: 299-309.
62. Asanuma M, Cadet JL. Methamphetamine-induced increase in striatal NF-kappaB DNA-binding activity is attenuated in superoxide dismutase transgenic mice. Brain Res Mol Brain Res 1998; 60: 305-9.
63. Asanuma M, Miyazaki I, Higashi Y, Tsuji T, Ogawa N. Specific gene expression and possible involvement of inflammation in methamphetamine-induced neurotoxicity. Ann NY Acad Sci 2004; 1025: 69-75.
64. Clark KH, Wiley CA, Bradberry CW. Psychostimulant abuse and neuroinflammation: emerging evidence of their interconnection. Neurotox Res 2013; 23: 174-88.
65. Snider SE, Hendrick ES, Beardsley PM. Glial cell modulators attenuate methamphetamine self-administration in the rat. Eur J Pharmacol 2013; 701: 124-30.
66. Snider SE, Vunck SA, van den Oord EJ, Adkins DE, McClay JL, Beardsley PM. The glial cell modulators, ibudilast and its amino analog, AV1013, attenuate methamphetamine locomotor activity and its sensitization in mice. Eur J Pharmacol 2012; 679: 75-80.
67. Chen H, Wu J, Zhang J, et al. Protective effects of the antioxidant sulforaphane on behavioral changes and neurotoxicity in mice after the administration of methamphetamine. Psychopharmacology 2012; 222: 37-45.
68. Beardsley PM, Hauser KF. Glial modulators as potential treatments of psychostimulant abuse. Adv Pharmacol 2014; 69: 1-69.
69. Wires ES, Alvarez D, Dobrowolski C, et al. Methamphetamine activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) and induces human immunodeficiency virus (HIV) transcription in human microglial cells. J Neurovirol 2012; 18: 400-10.
70. Thomsen M, Caine SB. Psychomotor stimulant effects of cocaine in rats and 15 mouse strains. Exp Clin Psychopharmacol 2011; 19: 321-41.
71. Wang HY, Burns LH. Naloxone's pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphine. PLoS One 2009; 4: e4282.